That’s because Viatris was formed through the merger of Mylan and Upjohn, the generics unit of Pfizer (NYSE:PFE). Pfizer shareholders were given a little more than 12 shares in Viatris for every 100 they held in Pfizer. Mylan shareholders got a Viatris share for every previous Mylan share they held.
What is the cost basis for Viatris?
This results in a tax basis of approximately $4.19 per share, with approximately $519.67 allocated to the 124 shares received of Viatris common stock and approximately $0.33 allocated to the Viatris fractional share in respect of which cash is received.
Should I sell Viatris stock?
There are currently 1 sell rating, 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “hold” Viatris stock.
Is Viatris spin off taxable?
Pfizer spun off its Upjohn unit which immediately merged with Mylan to form Viatris, effective November 16, 2020 in a transaction meant to be tax-free to Pfizer shareholders. … This action is a standard spinoff transaction in the accounting software. It is structured to be a non-taxable event for Pfizer shareholders.
What will Viatris dividend be?
On May 7, 2021, Viatris’ Board of Directors declared the Company’s first quarterly cash dividend of $0.11 per share on the Company’s issued and outstanding common stock. The cash dividend will be payable on June 16, 2021 to shareholders of record as of the close of business on May 24, 2021.
Does Viatris pay a dividend?
When does Viatris pay dividends? Viatris pays a dividend 2 times a year. Payment months are June, September.
Is Viatris a Pfizer company?
A: Viatris is a new company that is the combination of Mylan and Upjohn, a legacy division of Pfizer.
Who owned Viatris?
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn on November 16, 2020.
In the transaction, GE received approximately $2.9 billion in cash as well as shares of Wabtec common stock and Wabtec non-voting convertible preferred stock that, together, represent an approximately 24.9% ownership interest in Wabtec.
What is the outlook for Viatris?
The 13 analysts offering 12-month price forecasts for Viatris Inc have a median target of 18.00, with a high estimate of 23.00 and a low estimate of 15.00. The median estimate represents a +35.75% increase from the last price of 13.26.